ReviewTherapeutic advances in gastroenterology2023
The treatment principles and targets for intestinal Behcet's disease.
Review in Therapeutic advances in gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- S100 proteins in IgA vasculitis and other systemic vasculitides - from pathogenic mechanisms to clinical biomarkers: a systematic review.Frontiers in immunology · 2026Pooled it
- Abdominal manifestations of multisystem diseases: a pattern-based imaging review.Abdominal radiology (New York) · 2026Review
- The "two flowers therapy": clinical efficacy and mechanisms of a total glucosides of paeony -colchicine dual-drugs for Behçet's disease derived from Chinese physicians' medication experience.Frontiers in immunology · 2026Observational
- Predictors of anti-TNF treatment failure in intestinal Behçet's disease: a multicenter retrospective cohort study.Clinical rheumatology · 2025Article
- Therapeutic effect of adalimumab in the treatment of intestinal Behçet's disease in children.Frontiers in pediatrics · 2025Article
- Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.Clinical and experimental medicine · 2024Article
- Intestinal ultrasound for intestinal Behçet disease reflects endoscopic activity and histopathological findings.Intestinal research · 2024Article
- Intestinal Behcet's Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behcet's disease (BD) is a chronic and recurrent systemic vasculitis involving large, medium and small blood vessels as well as arteries and veins. BD with predominant gastrointestinal manifestations is diagnosed as intestinal BD, which is associated with severe complications such as massive gastrointestinal hemorrhage, perforation, and obstruction. Recently, treat-to-target (T2T) strategies have been successfully used in many chronic diseases and been suggested in the management of BD, while there are no related reviews about the global treatment strategy including treatment principles and targets for intestinal BD in detail. Herein, we review the treatment principles from the aspects of departments of Rheumatology and Gastroenterology. In addition, treatment targets of intestinal BD are reviewed from three aspects such as evaluable markers, effective markers and potency-ratio markers. Some definitions and conceptions from inflammatory bowel disease (IBD) bring us reference and enlightenments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.